<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02681952</url>
  </required_header>
  <id_info>
    <org_study_id>DW_RNMZ_401</org_study_id>
    <nct_id>NCT02681952</nct_id>
  </id_info>
  <brief_title>A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical&#xD;
      Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and&#xD;
      Kremezin in Pre-dialysis Patients With Chronic Renal Failure&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preference of formulation</measure>
    <time_frame>24weeks</time_frame>
    <description>questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>12weeks, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Indoxyl sulfate</measure>
    <time_frame>12weeks, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin-C</measure>
    <time_frame>12weeks, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated GFR(Glomerular Filtration Rate)</measure>
    <time_frame>12weeks, 24weeks</time_frame>
    <description>MDRD GFR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>Renamezin-&gt;Kremezin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Kremezin-&gt;Renamezin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Renamezin capsule</intervention_name>
    <arm_group_label>Kremezin-&gt;Renamezin</arm_group_label>
    <arm_group_label>Renamezin-&gt;Kremezin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kremezin granule</intervention_name>
    <arm_group_label>Kremezin-&gt;Renamezin</arm_group_label>
    <arm_group_label>Renamezin-&gt;Kremezin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pre-dialysis patients with chronic renal failure stage&#xD;
&#xD;
          -  patient for holding the stable state in serum creatinine 2.0mg/dl - 5.0mg/dl of MDRD&#xD;
             GFR 15-60ml/min/1.73m2 for 3 months before screening&#xD;
&#xD;
          -  patients haven't experienced dose spherical carbon adsorbent for 3months before&#xD;
             screening&#xD;
&#xD;
          -  patients who were no noticeable change for 4weeks before screening and are expected to&#xD;
             change is not needed during therapy in the therapy of chronic renal failure(type of&#xD;
             blood pressure medication and dose -related, diet therapy)&#xD;
&#xD;
          -  patients spontaneously written consent to participate in this clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with passes through the digestive tract disorders&#xD;
&#xD;
          -  patients with uncontrolled constipation symptoms&#xD;
&#xD;
          -  kidney transplant patients&#xD;
&#xD;
          -  patients who are taking immunosuppressive drugs&#xD;
&#xD;
          -  patients suffering from digestive tract ulcers and esophageal varices&#xD;
&#xD;
          -  patients with uncontrolled hypertension&#xD;
&#xD;
          -  patients hospitalized with cardiovascular disease within 3 months of the screening&#xD;
&#xD;
          -  patients with current infections&#xD;
&#xD;
          -  patients who do not fulfill therapies of chronic renal failure (taking medicine and&#xD;
             diet) as appropriate&#xD;
&#xD;
          -  patients with hepatic impairment (2.5 times greater than the upper limit of normal&#xD;
             levels of AST, ALT)&#xD;
&#xD;
          -  uncontrolled diabetes (HbA1c &gt; 10 % or a fasting glucose &gt; 180mg / dL)&#xD;
&#xD;
          -  patients with malignant tumors (However, if you do not relapse within five years after&#xD;
             completion of therapy can be registered)&#xD;
&#xD;
          -  pregnant women, nursing mothers&#xD;
&#xD;
          -  those who do not agree to a contraceptive method allowed for the possibility of&#xD;
             pregnancy in women&#xD;
&#xD;
          -  patients participating in another clinical trial in addition to the current clinical&#xD;
             trial&#xD;
&#xD;
          -  subjects with dependency on drugs or alcohol&#xD;
&#xD;
          -  subjects who took any other investigational drugs within 30 days before participating&#xD;
             this clinical trial study&#xD;
&#xD;
          -  patients expected to starting the dialysis within three months&#xD;
&#xD;
          -  other patients deemed unsuitable tester&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bumseok Kim, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sevrance Hospital of Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sevrance Hospital of Yonsei University</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <last_update_submitted>July 4, 2017</last_update_submitted>
  <last_update_submitted_qc>July 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

